Lithotripsy

Our Mayberry Annouces New Partnership With NextMed

Retrieved on: 
Friday, November 13, 2020

TUCSON, Ariz., Nov. 13, 2020 /PRNewswire/ --"We are excited to announce today that two NextMed Holdings companies have joined the Our Mayberry platform, said Our Mayberry CEO, Shawn Tacey.

Key Points: 
  • TUCSON, Ariz., Nov. 13, 2020 /PRNewswire/ --"We are excited to announce today that two NextMed Holdings companies have joined the Our Mayberry platform, said Our Mayberry CEO, Shawn Tacey.
  • The two companies NextMed Laser and Maritime Lithotripsy provide the highest possible level of medical services, focused on treating conditions like kidney stones.
  • NextMed was founded in Tucson, AZ in 1996, and has since grown to support 1,000s of physicians and facilities across the United States.
  • Taceyhighlighted extensions of the Our Mayberry financial technology capabilities as helping to secure the relationship with NextMed.

EDAP Announces Presentation at the Jefferies Virtual London Healthcare Conference

Retrieved on: 
Tuesday, November 10, 2020

The webcast will be archived and available for replay for a period of 90 days.

Key Points: 
  • The webcast will be archived and available for replay for a period of 90 days.
  • A recognized leader in the global therapeutic ultrasound market,EDAP TMSdevelops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
  • EDAP TMS also produces and distributes other medical equipment such as the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL).

EDAP TMS SA to Announce Third Quarter 2020 Financial Results on November 18, 2020

Retrieved on: 
Monday, November 9, 2020

A recognized leader in the global therapeutic ultrasound market,EDAP TMSdevelops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.

Key Points: 
  • A recognized leader in the global therapeutic ultrasound market,EDAP TMSdevelops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
  • EDAP TMS also produces and distributes other medical equipment including the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL).
  • For more information on the Company, please visit http://www.edap-tms.com , and us.hifu-prostate.com .

Global Kidney Stone Retrieval Devices Market Forecast to 2027 - COVID-19 Impact and Analysis

Retrieved on: 
Monday, November 2, 2020

DUBLIN, Nov. 2, 2020 /PRNewswire/ -- The "Kidney Stone Retrieval Devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; Treatment; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 2, 2020 /PRNewswire/ -- The "Kidney Stone Retrieval Devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; Treatment; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The key factors driving the growth of the market include increasing incidence of kidney stone disease and escalating number of kidney stone retrieval device launches.
  • Based on type, the kidney stone retrieval devices market is segmented into lithotripters, stone removal devices, ureteral stents, and ureterorenoscopes.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
    6.2 Global Kidney Stone Retrieval Devices Market, By Geography - Forecast And Analysis
    7.2 Kidney Stone Retrieval Devices Market Revenue Share, by Type (2019 and 2027)
    8.2 Kidney Stone Retrieval Devices Market Revenue Share, by Treatment (2019 and 2027)
    8.3.1 Extracorporeal Shock Wave Lithotripsy: Kidney Stone Retrieval Devices Market - Revenue and Forecast to 2027 (US$ Million)
    9.2 Kidney Stone Retrieval Devices Market Revenue Share, by Process (2019 and 2027)
    10.4 Middle East and Africa: Kidney Stone Retrieval Devices Market
    10.5 South and Central America: Kidney Stone Retrieval Devices Market
    11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic
    12.2 Growth Strategies Done by the Companies in the Market, (%)

Shockwave Announces Updated Time for CAD III Investor Webcast Event in Conjunction with TCT Connect

Retrieved on: 
Thursday, October 1, 2020

SANTA CLARA, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced updated timing for the companys CAD III Investor Webcast Event to be held in conjunction with TCT Connect.

Key Points: 
  • SANTA CLARA, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced updated timing for the companys CAD III Investor Webcast Event to be held in conjunction with TCT Connect.
  • The webcast event will include a presentation of the DISRUPT CAD III trial results by one of the studys principal investigators as well as a panel discussion and an interactive question and answer session.
  • Interested parties may access a live audio webcast of the presentation by visiting the Investors section of the companys website at https://ir.
  • Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

Shockwave Medical to Participate in Upcoming September Investor Conferences

Retrieved on: 
Wednesday, August 26, 2020

SANTA CLARA, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Shockwave management is scheduled to speak at the following upcoming virtual investor conferences:

Key Points: 
  • SANTA CLARA, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Shockwave management is scheduled to speak at the following upcoming virtual investor conferences:
    The 2020 Wells Fargo Virtual Healthcare Conference, Wednesday, September 9, 2020, at 2:40 p.m. Eastern Time
    The Morgan Stanley Virtual 18th Annual Global Healthcare Conference, Thursday, September 17, 2020, at 2:45 p.m. Eastern Time
    Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.
  • The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL).
  • IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes.
  • To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com .

EDAP TMS SA to Announce Second Quarter 2020 Financial Results on August 26, 2020

Retrieved on: 
Wednesday, August 19, 2020

A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology.

Key Points: 
  • A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology.
  • By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm Robotic HIFU and Ablatherm Fusion.
  • As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith range of ESWL systems.
  • For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

Shockwave Medical to Present at the Canaccord Genuity 40th Annual Growth Conference

Retrieved on: 
Thursday, July 30, 2020

SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11 to 13, 2020.

Key Points: 
  • SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11 to 13, 2020.
  • Shockwave's management is scheduled for a live fireside chat on Wednesday, August 12, 2020, at 2:30 p.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the event on the "Investors" section of the companys website at https://ir.shockwavemedical.com .
  • Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

Shockwave Medical to Report Second Quarter 2020 Financial Results on August 11, 2020

Retrieved on: 
Tuesday, July 21, 2020

SANTA CLARA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter 2020 after market close on Tuesday, August 11, 2020.

Key Points: 
  • SANTA CLARA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter 2020 after market close on Tuesday, August 11, 2020.
  • Company management will host a corresponding teleconference that will be webcasted live beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call may do so by dialing (866) 795-9106 for domestic callers or (470) 495-9173 for international callers, using conference ID: 8889064.
  • Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

Shockwave Appoints Maria Sainz to Board of Directors

Retrieved on: 
Monday, July 20, 2020

SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors and will serve on Shockwaves Compensation Committee.

Key Points: 
  • SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors and will serve on Shockwaves Compensation Committee.
  • I am delighted to welcome Maria to our Board of Directors, said Doug Godshall, President and Chief Executive Officer of Shockwave Medical.
  • Ms. Sainz has been intimately involved in the launches of several significant medical technology products including coronary stents and cardiac resynchronization therapy devices.
  • I am honored to join the Shockwave Medical Board of Directors, said Ms. Sainz.